Waterloo Capital L.P. Acquires 793 Shares of Gilead Sciences, Inc. $GILD

Waterloo Capital L.P. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.3% during the second quarter, HoldingsChannel.com reports. The fund owned 3,174 shares of the biopharmaceutical company’s stock after purchasing an additional 793 shares during the quarter. Waterloo Capital L.P.’s holdings in Gilead Sciences were worth $352,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD increased its stake in Gilead Sciences by 314.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences in the second quarter worth about $238,083,000. Vanguard Group Inc. lifted its holdings in Gilead Sciences by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its position in shares of Gilead Sciences by 345.7% during the 1st quarter. Mackenzie Financial Corp now owns 2,500,209 shares of the biopharmaceutical company’s stock valued at $280,148,000 after acquiring an additional 1,939,273 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 1.1%

Shares of GILD stock opened at $125.27 on Tuesday. The firm has a market capitalization of $155.42 billion, a P/E ratio of 24.95, a PEG ratio of 0.81 and a beta of 0.32. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The firm’s fifty day moving average price is $118.73 and its two-hundred day moving average price is $113.94.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the company posted $2.02 earnings per share. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research analyst reports. Argus raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $143.00 to $147.00 and gave the stock an “overweight” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the sale, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,146 shares of company stock valued at $15,148,441 in the last three months. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.